- Home
- PAY vs MRUS Comparison
PAY vs MRUS Comparison
Compare PAY & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAY
- MRUS
- Stock Information
- Founded
- PAY 2004
- MRUS 2003
- Country
- PAY United States
- MRUS Netherlands
- Employees
- PAY N/A
- MRUS N/A
- Industry
- PAY Computer Software: Prepackaged Software
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- PAY Technology
- MRUS Health Care
- Exchange
- PAY Nasdaq
- MRUS Nasdaq
- Market Cap
- PAY 4.8B
- MRUS 4.1B
- IPO Year
- PAY 2021
- MRUS 2016
- Fundamental
- Price
- PAY $32.05
- MRUS $53.11
- Analyst Decision
- PAY Hold
- MRUS Strong Buy
- Analyst Count
- PAY 5
- MRUS 12
- Target Price
- PAY $36.40
- MRUS $87.92
- AVG Volume (30 Days)
- PAY 712.6K
- MRUS 2.0M
- Earning Date
- PAY 08-07-2025
- MRUS 07-31-2025
- Dividend Yield
- PAY N/A
- MRUS N/A
- EPS Growth
- PAY 74.18
- MRUS N/A
- EPS
- PAY 0.40
- MRUS N/A
- Revenue
- PAY $962,105,000.00
- MRUS $54,732,000.00
- Revenue This Year
- PAY $27.22
- MRUS $75.57
- Revenue Next Year
- PAY $20.11
- MRUS $31.84
- P/E Ratio
- PAY $80.33
- MRUS N/A
- Revenue Growth
- PAY 47.78
- MRUS 42.77
- 52 Week Low
- PAY $16.94
- MRUS $33.19
- 52 Week High
- PAY $40.43
- MRUS $62.98
- Technical
- Relative Strength Index (RSI)
- PAY 34.38
- MRUS 53.18
- Support Level
- PAY $32.33
- MRUS $52.41
- Resistance Level
- PAY $34.00
- MRUS $54.59
- Average True Range (ATR)
- PAY 1.46
- MRUS 2.15
- MACD
- PAY -0.73
- MRUS -0.77
- Stochastic Oscillator
- PAY 2.45
- MRUS 7.62
About PAY Paymentus Holdings Inc.
Paymentus Holdings Inc provides electronic bill presentment and payment services, enterprise customer communication and self-service revenue management to billers and financial institutions through a Software-as-a-Service, (SaaS), secure, omni-channel technology platform. The platform integrates into a biller's core financial and operating systems to provide flexible and secure access to payment processing of credit cards, debit cards, eChecks and digital wallets across a number of channels including online, mobile, IVR, call center, chatbot and voice-based assistants. The Company generates revenue from payment transaction fees processed through the Company's platform. The fees are generated as a percentage of transaction value or a specified fee per transaction.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.